The expression of QKI variant 5 (QKI-V5) was downregulated in the blood of individuals with central nervous system (CNS)-inflammatory demyelinating diseases and may play a role in the remyelination process.
Why this matters
Neuromyelitis optica (NMO) and multiple sclerosis (MS) are demyelinating diseases caused by inflammation that damages oligodendrocytes. Very few therapies aim to treat demyelination by enhancing the remyelination process and to promote the proliferation/differentiation of oligodendrocytes at the site of lesion. Results from this study provide evidence that more research is necessary to elucidate the role QKI plays in demyelinating diseases.